Upstream Bio (UPB) Stock Price, News & Analysis

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $15.51 to $17.06
• 50-Day Range: $16.11 to $27.39
• 52-Week Range: $14.97 to $29.46
• Volume: 3.88 million shs
• Average Volume: 370,503 shs
• Market Capitalization: $868.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.50
• Consensus Rating: Buy

Upstream Bio Stock Analysis - MarketRank™

Upstream Bio scored higher than 41% of companies evaluated by MarketBeat, and ranked 679th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Upstream Bio has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for UPB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Upstream Bio does not currently pay a dividend.

Dividend Growth

Upstream Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for UPB.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.40

News Sentiment

Upstream Bio has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Upstream Bio this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for UPB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Upstream Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $34,000,000.00 in company stock and sold $0.00 in company stock.

UPB Stock Analysis - Frequently Asked Questions

How have UPB shares performed this year?

Upstream Bio's stock was trading at $22.00 at the beginning of 2024. Since then, UPB shares have decreased by 26.3% and is now trading at $16.21.
View the best growth stocks for 2024 here.

How were Upstream Bio's earnings last quarter?

Upstream Bio, Inc. (NASDAQ:UPB) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $6.38. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $0.83 million.

When did Upstream Bio IPO?

Upstream Bio (UPB) raised $200 million in an initial public offering on Friday, October 11th 2024. The company issued 12,500,000 shares at $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair served as the underwriters for the IPO.

When did the company's quiet period expire?

Upstream Bio's quiet period expired on Wednesday, November 20th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Upstream Bio?

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 11/07/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:UPB
• Previous Symbol: NASDAQ:UPB
• CUSIP: N/A
• CIK: 2022626
• Web: upstreambio.com
• Phone: (781) 208-2466
• Fax: N/A
• Employees: 38
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $56.50
• High Stock Price Target: $75.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +248.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.21 million
• Price / Sales: 393.66
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,597,000
• Free Float: N/A
• Market Cap: $868.81 million
• Optionable: N/A
• Beta: N/A